Case Report

Omalizumab biosimilar, a cost effective option for patients with chronic urticaria: Our initial experience in two cases

Nidhi Sharma¹*, Ramanjit Singh¹, Anant Patil²

¹Dept. of Dermatology, Medanta, The Medicity, Gurugram, Haryana, India
²Dept. of Pharmacology, Dr. DY Patil Medical College, Neral, Navi Mumbai, Maharashtra, India

ABSTRACT

Chronic urticaria is a heterogenous skin condition. Second generation antihistamines are considered as first line treatment. In patients who do not respond to normal dose, second generation non-sedating antihistamines can be increased up to four fold. Some patients do not respond to higher dose of second generation non-sedating antihistamines. Omalizumab is an attractive option for such patients with chronic urticaria. However, cost of omalizumab is an important limiting factor for its wide use. Now with the availability of omalizumab biosimilar in India, it usage may be increased. We report two cases of difficult to treat chronic urticaria who responded to omalizumab biosimilar.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Chronic urticaria is a dermatological disease with point prevalence of 1.4% in Asians compared to 0.5% and 0.1% in European and North Americans respectively.¹ Omalizumab, an anti-IgE biologic agent is an effective option for the treatment of chronic urticaria. This recombinant humanized anti-IgE monoclonal antibody provides quick and effective remission in patients not responding to other therapies.² Omalizumab is well tolerated without any major clinical concern² and effective in patients with chronic spontaneous urticaria resistant to antihistamines and having several comorbidities.³ Omalizumab is recommended as treatment for patients not responding to up to four fold dose of non-sedating antihistamines.⁴ ⁵

Biologics, although an attractive option, have a concern of cost.⁶ ⁷ especially in resource limited countries and for patients spending money from the pocket. Biosimilars are manufactured as an alternative to provide cost-effective interchangeable option for biologic.³ A study in Chinese healthy males showed dose dependent reduction in free IgE level after subcutaneous biosimilar omalizumab and it was well tolerated.⁸

Recently, omalizumab biosimilar has been introduced in the Indian market.⁹ There are no published studies with omalizumab biosimilar in Indian patients with chronic urticaria.

We report response with omalizumab biosimilar in two patients with chronic urticaria unresponsive to higher doses of second generation non-sedative antihistamines.

2. Case 1

A 24 year old male patient was a known case of chronic urticaria since 2 years. His previous treatments included levocetirizine 5 mg two tablets twice daily. After inadequate response to this, he was treated fexofenadine 180 mg two tablets twice daily and cyclosporine 3 mg/kg. However, this treatment also did not provide satisfactory response. There was no history of angioedema or comorbidities. D-dimer level was 0.27 mg/L (normal level <0.5 mg/L). Serum IgE level was 686 IU/ml and absolute eosinophil count level was 0.37 thou/mm³ (normal level 0.02-0.50 thou/mm³). Omalizumab 300 mg was administered subcutaneously.

*Corresponding author.
E-mail address: drnidhirsharma@gmail.com (N. Sharma).
Second dose of 300 mg was administered after one month.

3. Case 2

A 45 year old female was a known case of chronic urticaria since 5 years. She did not have any comorbidity. Her previous treatment included levocetirizine 10 mg one tablet twice daily. After inadequate response, she also received loratidine 10 mg two tablets twice daily. She did not tolerate cyclosporine started in the dose of 3 mg/kg per day and developed severe myalgia. Her serum ferritin level was low and C-reactive protein level was high (11 mg/L). She was tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Serum vitamin D level was low. Her D-dimer level was 4.26 mg/mL. Serum IgE level (2.42 KIU/L) and absolute eosinophil count levels were within normal limits. She was treated with omalizumab 300 mg subcutaneously.

Both patients were carefully observed for two hours after injection for any adverse events. They were advised to take one tablet of levocetitizine 5 mg as required. In both cases, satisfactory response to treatment was observed after omalizumab administration. Response to treatment i.e. Urticaria Activity Score (UAS) is shown in Figure 1.

Improvement in disease control as measured by Urticaria Control Test and quality of life of both patients is shown in Table 1. Significant reduction in consumption of second generation antihistamines was also observed in both cases. No adverse events were seen in both cases.

Table 1: Clinical characteristics and treatment response in two patients treated with omalizumab biosimilar

|                  | Urticaria Control Test score (Range 0-16) | Dermatology Life Quality Index score (Range 0-30) |
|------------------|------------------------------------------|-----------------------------------------------|
|                  | Baseline | After 1 month | Baseline | After 1 month |
| Case 1           | 3        | 12            | 15       | 5             |
| Case 2           | 2        | 12            | 18       | 3             |

Fig. 1: Urticaria Activity Score in two patients treated with omalizumab biosimilar

4. Discussion

Omalizumab is an attractive option for patients not responding to high dose of non-sedating antihistamines. A small retrospective study from Eastern India (n=24), reported response in 96% refractory cases of chronic spontaneous urticaria. In the study, investigators used omalizumab in patients not responding to up-dosing of antihistamines and cyclosporine.

Now, original and biosimilar omalizumab both are available in India. Biosimilar represents an economical option for patients who can not afford high cost of therapy.

Both of our patients successfully responded to treatment with omalizumab biosimilar. Both of them had received higher dose antihistamines. One patient received cyclosporine and did not respond to the treatment. Second patient did not tolerate cyclosporine.

In India, majority of the patients pay for healthcare from their pocket, posing high economic burden. Because of the cost constraint, many patients do not afford the treatment. A randomized clinical trial in India reported clinical comparability of omalizumab biosimilar with reference product. There was no significant difference in both products for the management of moderate to severe persistent asthma. Our initial experience with omalizumab biosimilar in patients with chronic urticaria is encouraging. It can be used as a cost effective alternative in patients not responding to higher doses of antihistamines.

5. Conclusion

In both treatment resistant cases of chronic urticaria, omalizumab biosimilar was found to be effective and well tolerated. Thus, our initial experience suggests that omalizumab biosimilar can be a useful option for patients with chronic urticaria who do not achieve satisfactory response with higher dose of second generation non-sedating antihistamines.

6. Source of Funding

No financial support was received for the work within this manuscript.

7. Conflict of Interest

The authors declare they have no conflict of interest.

References

1. Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423–32. doi:10.1111/all.14057
2. Lesiak A, Bednarski IA, Mačkowska A, Łukasik Z, Woźniacka A, Staruch JO, et al. Omalizumab for urticaria treatment in clinical practice: a case series. *Adv Dermatol Allergol*. 2018;35(4):372–4.

3. Vollono L, Piccolo A, Lanna C, Esposito M, Bavetta M, Campione E, et al. Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice. *Drug Design Dev Ther*. 2019;13:3181–6.

4. Zuberbier T, Aberer W, Asero R, Latiff A, Baker D, Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. *Allergy*. 2018;73:1393–414.

5. Godse K, Rajagopalan M, Girdhar M, Kandhari S, Shah B, Chhajed PN, et al. Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients. *Indian Dermatol Online J*. 2016;7(1):6–11.

6. Blackstone EA, Fuhr JP. The economics of biosimilars. *Am Health Drug Benefits*. 2013;6:469–78.

7. Kaida-Yip F, Deshpande K, Saran T, Vyas D. Biosimilars: Review of current applications, obstacles, and their future in medicine. *World J Clin Cases*. 2018;6(8):161–6. [DOI: 10.12998/wjcc.v6i8.161]

8. Zhou B, Lin B, Li J, Qian W, Hou S, Zhang D, et al. Pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects. *mAbs*. 2012;4:110–9.

9. OmaliRel; 2020. Available from: [https://www.rellife.com/web/lifesciences/omalirelAccessed on 26th].

10. Neema S, Chatterjee M. Omalizumab for management of refractory urticaria: Experience of a tertiary care centre in Eastern India. *Indian J Dermatol*. 2018;63(1):61–5. [DOI: 10.4103/ijd.jdd_542_17]

11. Apsangikar P, Ghadge P, Naik M, Nair S. Randomized comparative clinical study of first global omalizumab biosimilar with innovator product in moderate to severe persistent asthma. *J Physician Assoc India*. 2020;68:61–5.

**Author biography**

**Nidhi Sharma**, Consultant Dermatology

**Ramanjit Singh**, Consultant Dermatology

**Anant Patil**, Assistant Professor

---

**Cite this article**: Sharma N, Singh R, Patil A. Omalizumab biosimilar, a cost effective option for patients with chronic urticaria: Our initial experience in two cases. *IP Indian J Clin Exp Dermatol* 2021;7(1):78-80.